Article
Asthma in children: update on diagnosis and management
- Aust Prescr 2026;49:218-24
- 1 December 2026
- DOI: 10.18773/austprescr.2026.050


The Australian Asthma Handbook was updated in 2025 and emphasises the importance of accurate diagnosis of asthma in children aged under 12 years and the early initiation of maintenance therapy with an inhaled corticosteroid (ICS) to reduce exacerbations and hospitalisation.
Diagnosis is based on clinical features and objective evidence of variable airflow limitation (spirometry and/or fractional exhaled nitric oxide testing). Alternative diagnoses should be considered, particularly in younger children with wheeze.
A stepwise approach to treatment is recommended, guided by symptom frequency and severity. A low-dose daily ICS is recommended for children with frequent symptoms or a history of exacerbations requiring systemic corticosteroid treatment. If asthma remains poorly controlled despite daily ICS therapy, a daily long-acting beta2 agonist may be added from 6 years of age. As-needed salbutamol, via a metered dose inhaler with a spacer, is recommended for symptom relief in children with mild wheezing with difficulty breathing or infrequent asthma symptoms.
Treatment adherence, inhaler technique and asthma control should be reviewed regularly. All children should have a personalised asthma action plan.
Referral to a paediatrician or paediatric respiratory physician is recommended if the diagnosis is uncertain, symptoms remain poorly controlled despite optimised treatment or more intensive therapies are being considered.
Asthma is one of the most common chronic conditions in childhood and a leading cause of disease burden for children in Australia.1 In 2022, an estimated 10% of Australian children aged 14 years and under were reported to have asthma.2 This prevalence is stable; however, underdiagnosis and undertreatment remain common, contributing to avoidable symptoms, exacerbations and hospitalisations. Between July 2023 and June 2024, there were approximately 13,600 hospitalisations for asthma among children aged 14 years and under.2
The Australian Asthma Handbook was updated in 2025 to include important changes to the diagnosis and management of asthma in children under 12 years of age.3 The updated guidelines place greater emphasis on confirming the diagnosis using objective evidence while recognising the challenges of diagnosing asthma in young children, and initiating anti-inflammatory treatment with an inhaled corticosteroid (ICS) earlier in the disease course.3
This article summarises the key changes to the diagnosis and management of asthma in children under 12 years of age. The management of asthma in adolescents (age 12 years and over) and adults is addressed in a separate article in this issue of the journal.4
Asthma is a heterogeneous disease with multiple different pathophysiological mechanisms. The Global Initiative for Asthma (GINA) recognises 5 phenotypes of asthma relevant to children: allergic asthma, non-allergic asthma, cough-predominant asthma, asthma with persistent airflow limitation, and asthma with obesity.5 These phenotypes are associated with different clinical presentations and responses to treatment.
In children, allergic asthma is the predominant phenotype and is recognisable through its association, either directly or through family history, with other allergic conditions, such as eczema, allergic rhinitis and food or drug allergy. Allergic asthma usually responds well to ICS treatment.5 In children with allergic asthma whose symptoms are poorly controlled, testing for specific allergic triggers through either skin prick or allergen-specific IgE testing should be considered and may guide management through allergen minimisation and/or immunotherapy.3
In children under 5 years of age, one of the more common clinical presentations is viral-induced wheezing or episodic viral wheeze, which is characterised by wheezing only during viral respiratory infections with no symptoms between episodes. Distinguishing episodic viral wheeze from asthma can be difficult in young children, and viral respiratory infections can trigger severe acute asthma exacerbations. Both GINA and the Australian Asthma Handbook now recognise that young children with recurrent or severe wheezing who consistently respond to a short-acting beta2 agonist (SABA; e.g. salbutamol) may benefit from guideline-recommended management, including maintenance ICS therapy, even when the cause of the wheezing is uncertain.3,5
A diagnosis of asthma in children is suggested by respiratory symptoms and features on history and physical examination (Table 1).3 Physical examination should include:
In children from 6 years of age, confirmation of asthma requires objective evidence of variable expiratory airflow limitation or airway inflammation using spirometry or fractional exhaled nitric oxide (FeNO) testing, because diagnosis based on history alone is associated with significant overdiagnosis.3,6 In children younger than 6 years, objective testing is not routinely recommended for diagnosis because reliable and repeatable results are often difficult to obtain.
Asthma should not be diagnosed in children younger than 12 months of age because symptoms in this age group are usually caused by bronchiolitis, which requires different management.7
Table 1 Features suggesting higher or lower probability of asthma in children3
| Asthma more likely | Asthma less likely |
|
|
| NB1: In children aged 1 to 5 years, wheezing that only occurs during viral respiratory infections may not be due to asthma, but this finding does not rule out asthma. Viral respiratory infection is the most common trigger for severe acute asthma exacerbations in children of all ages. Reproduced, with permission, from the Australian Asthma Handbook.3 | |
An ICS trial can aid asthma diagnosis in children aged 1 to 5 years.3 An 8- to 12-week trial of maintenance low-dose ICS is recommended for children with frequent symptoms (daytime symptoms at least twice per week or night-time symptoms at least twice per month), recurrent wheezing (more than 4 episodes per year) or severe wheezing. The trial should be undertaken when a child is likely to be exposed to their typical triggers.3
Spirometry, including bronchodilator responsiveness testing, is recommended for children from 6 years of age. A key change in the 2025 Australian Asthma Handbook is that FeNO testing is now also recommended.3 FeNO testing provides an accurate indication of active airway inflammation, one of the key features supporting an asthma diagnosis.5 FeNO testing is increasingly available through respiratory testing services.
An asthma diagnosis is confirmed by a positive bronchodilator responsiveness test, defined as an increase in forced expiratory volume in 1 second (FEV1) of more than 10% of the predicted FEV1 value 10 to 15 minutes after the administration of a rapid-acting bronchodilator (e.g. salbutamol), or an elevated FeNO of at least 25 parts per billion.3 Children should be referred to a paediatrician or paediatric respiratory physician if the diagnosis cannot be confirmed by spirometry or FeNO testing.3
Long-term asthma management in children aims to maintain good symptom control and prevent exacerbations while minimising the adverse effects of medication. Good symptom control is defined as infrequent (less than 2 days per week), brief and non-disruptive daytime symptoms and the absence of night-time symptoms.3 A stepwise treatment approach is recommended, tailored to symptom frequency and severity and the risk of exacerbations. Treatment may need to be adjusted over time, and many children will outgrow their asthma and enter remission. If asthma has been well controlled for at least 3 months despite exposure to known triggers, consider stepping down treatment and arrange follow-up within 3 to 6 weeks to reassess symptom control and update the asthma action plan.
Children aged 1 to 5 years often experience episodic wheeze, which can occur with or without underlying asthma. Salbutamol can be used as needed when a child experiences mild wheezing with difficulty breathing, even if the cause is uncertain.3
Daily low-dose ICS therapy is recommended for children aged 1 to 5 years with frequent asthma symptoms (daytime symptoms at least twice per week or night-time symptoms at least twice per month), a history of 2 or more exacerbations requiring emergency department presentation or systemic corticosteroid treatment in the past 12 months, or at least one life-threatening exacerbation requiring hospitalisation. A daily low-dose ICS may also be initiated in children with recurrent wheezing (more than 4 episodes per year) or severe wheezing.3 The threshold for initiating daily low-dose ICS in children has been lowered in the 2025 guideline3 to support the earlier reduction of future exacerbations and reduce cumulative exposure to repeated courses of oral corticosteroids,8 which are associated with adverse effects in children, such as growth suppression.9,10
In children aged 1 to 5 years who require maintenance therapy with a low-dose ICS, fluticasone propionate 50 micrograms twice daily is recommended. If asthma symptoms are not well controlled after 3 months of therapy, the common causes of poor symptom control (e.g. inhaler technique, adherence, exposure to triggers) should be assessed and managed before an increase in the fluticasone dose to 100 micrograms twice a day is considered. Alternatively, daily oral montelukast can be considered in children from 2 years of age when parents decline ICS treatment. Monitoring for behavioural or neuropsychiatric adverse effects (e.g. depression, agitation, aggression, nightmares, hallucinations) is recommended.3,11 These effects tend to occur within 2 weeks of initiation and resolve with cessation of the medication.12
In children aged 4 years or older whose asthma is not adequately controlled, the addition of daily inhaled salmeterol, a long-acting beta2 agonist (LABA), to low-dose ICS therapy can be considered while waiting for advice from a paediatrician or paediatric respiratory physician.3 The addition of a LABA to an ICS in this age group does not increase the risk of exacerbations, in contrast to historical concerns.13,14
Asthma treatment for children aged 6 to 11 years usually consists of as-needed inhaled SABAs (e.g. salbutamol) to relieve symptoms and, in children who require long-term treatment, daily ICS therapy to reduce airway inflammation and prevent exacerbations (Figure 1).3
Figure summarising the National Asthma Council’s Australian Asthma Handbook stepwise approach to asthma treatment in children aged 6 to 11 years. The starting treatment level depends on the child’s frequency and severity of asthma symptoms and their risk of exacerbations. Treatment may be stepped up if good symptom control is not achieved despite good adherence and correct inhaler technique. Treatment may be stepped down if asthma is well controlled for at least 3 months. Treatment level 1 is inhaled salbutamol as needed for symptom relief; treatment level 2 is a low-dose maintenance inhaled corticosteroid (ICS) plus as-needed salbutamol; treatment level 3 is a low-dose maintenance ICS in combination with a long-acting beta2 agonist (LABA; e.g. salmeterol) or a medium-dose maintenance ICS, plus as-needed salbutamol; treatment level 4 is a medium-dose maintenance ICS in combination with a LABA, plus as-needed salbutamol; treatment level 5 is targeted intensive treatment that requires specialist management (e.g. by a paediatrician or paediatric respiratory physician).
Children aged 6 to 11 years with mild or infrequent symptoms can be treated with as-needed inhaled salbutamol (Figure 1, treatment level 1). However, the use of 3 or more salbutamol inhalers a year indicates poor asthma control and should prompt initiation of an ICS.15
For children aged 6 to 11 years with frequent symptoms or a history of an exacerbation requiring systemic corticosteroid treatment in the past 12 months, low-dose maintenance ICS therapy is recommended (Figure 1, treatment level 2). A medium-dose ICS or low-dose ICS plus a LABA can be initiated if symptoms are severe or there is a high risk of exacerbation (Figure 1, treatment level 3).3 An ICS at a dose appropriate to control symptoms greatly reduces the frequency and severity of asthma symptoms and the risk of hospitalisation.5 The addition of a LABA to a low-dose ICS is recommended as an alternative to medium-dose ICS therapy to maintain effective asthma control while minimising long-term cumulative corticosteroid exposure.3
Recent international guidelines suggest an emerging role for as-needed ICS+formoterol therapy (i.e. anti-inflammatory reliever [AIR] therapy), instead of daily maintenance ICS therapy plus an as-needed SABA, in children aged 6 years and older with mild asthma.5 Although AIR therapy is recommended in adolescents and adults,4 it is not currently approved for children younger than 12 years of age, and evidence in this age group is limited.
Doses of inhaled medications used for asthma maintenance therapy in children are provided in Table 2.
Table 2 Inhaled medications used as maintenance therapy in children aged 1 to 11 years with asthma3,16
| Medication | Inhaler device type (device brand name) | Strength (micrograms) | Recommended ICS dose | TGA-approved age group |
|
fluticasone propionate (first-line ICS) [NB1] |
pMDI Dry powder inhaler (Accuhaler) |
pMDI: 50, 125 Dry powder inhaler: 100 |
Low dose: 50 micrograms twice daily Medium dose: 100 micrograms twice daily (up to 8 years of age) or 100 to 125 micrograms twice daily (8 to 11 years of age)3 |
pMDI: age 1 year and above Dry powder inhaler: age 5 years and above |
|
ciclesonide (first-line ICS) [NB1] |
pMDI |
80, 160 |
Low dose: 80 micrograms once daily Medium dose: 160 micrograms once daily |
Age 6 years and above |
|
beclometasone (second-line ICS) |
pMDI |
50, 100 |
Low dose: 50 micrograms twice daily Medium dose: 100 micrograms twice daily3 |
Age 5 years and above |
|
budesonide (second-line ICS) |
Dry powder inhaler (Turbuhaler) |
100, 200 |
Low dose: 100 micrograms daily Medium dose: 100 to 200 micrograms twice daily3 |
Age 5 years and above |
|
fluticasone propionate+salmeterol |
pMDI Dry powder inhaler (Accuhaler) |
pMDI: 50+25 Dry powder inhaler: 100+50 |
Medium dose: 100+50 micrograms twice daily |
Age 4 years and above [NB2] |
| ICS = inhaled corticosteroid; pMDI = pressurised metered dose inhaler; TGA = Therapeutic Goods Administration (Australia) NB1: The Australian Asthma Handbook recommends fluticasone propionate or ciclesonide as first-line maintenance ICS therapy for children aged 6 years and above, based on current evidence of their efficacy and safety. Fluticasone propionate is the only ICS recommended for children aged 1 to 5 years.3 NB2: The Australian Asthma Handbook recommends the use of fluticasone propionate+salmeterol inhaler only in children from 6 years of age.3 | ||||
Oral montelukast can be added to ICS-based treatment (Figure 1, treatment level 3), particularly in patients with concomitant allergic rhinitis. However, montelukast has not been shown to improve asthma control in children compared with ICS+LABA therapy.17 Patients and caregivers should be counselled on possible adverse effects, especially neuropsychiatric effects.
Common adverse effects of ICS therapy include hoarse voice (dysphonia), sore throat, mouth irritation and oral thrush. These adverse effects can be minimised by: using a spacer with a pressurised metered dose inhaler (pMDI); rinsing the mouth and spitting after inhaling a dose; and using the lowest effective ICS dose to achieve good asthma control.
At high doses (e.g. more than 200 micrograms daily of fluticasone propionate in a child less than 8 years of age), ICS therapy is associated with systemic adverse effects such as adrenal suppression. Growth suppression is most pronounced during the first year of ICS treatment.18 A randomised controlled trial found that children aged 5 to 13 years who received high-dose inhaled budesonide (400 micrograms daily) were on average 1.2 cm shorter than their peers who had not received budesonide after 4 to 6 years of treatment; this difference was sustained through to adulthood.10
All children with a diagnosis of asthma, or recurrent wheeze requiring preventer therapy, should have a personalised written asthma action plan. These outline day-to-day management and provide clear instructions for recognising and responding to worsening symptoms, including the use of a SABA (reliever). The plans should be simple and easily understood by parents, carers and school staff. Templates are available on the National Asthma Council’s website.
Clinicians should advocate for a smoke-free and vape-free home. Exposure to environmental tobacco smoke doubles the risk of hospitalisation for asthma.19
Routine pertussis vaccination is important for children with asthma. Children with severe asthma are at higher risk of severe influenza, and annual influenza vaccination is recommended.20
Routine allergen avoidance or reduction is not recommended unless the child has a proven sensitivity to the allergen and the allergen is a clinically significant asthma trigger.5
Appropriate device selection, inhaler technique and treatment adherence are key determinants of asthma control. The choice of inhaler depends on the child’s age and ability to use the inhaler correctly. Using placebo inhalers and educational videos (e.g. those available on Asthma Australia’s website) to assist with training can help ensure that an appropriate device is selected and used correctly.
pMDIs with spacers are generally recommended for children under 10 years of age, with well-fitting (sealed) face masks for children under 5 years of age and mouthpieces from 5 years of age. After a dose is actuated into the spacer, children aged 6 years and below should take 2 deep breaths in and out. For children aged 7 years and over, one deep breath is adequate.21
Dry powder inhalers (DPIs) are generally recommended for children aged 10 years and older. However, some children from 6 years of age can use a DPI effectively if they can generate adequate peak inspiratory flow.22 DPIs have a lower carbon footprint than pMDIs, which contain hydrofluorocarbon propellants.23
Asthma control, inhaler technique and treatment adherence should be reviewed regularly. Practical ways to assess adherence include reviewing prescription refill frequency and checking whether preventer inhalers are lasting for the expected duration based on the prescribed dose regimen. Increasing reliever use may indicate worsening asthma control.15
If there is poor or worsening asthma control, review adherence, inhaler technique, exposure to triggers and the possibility of an alternative diagnosis. Assess for comorbidities (e.g. rhinosinusitis, obesity, mental health conditions) and psychosocial factors (e.g. stressful life events, financial problems) that could be contributing to poor asthma control.3,5 If asthma remains poorly controlled despite addressing these factors, refer for repeat spirometry, assess the blood eosinophil count (a marker of eosinophilic inflammation and required for consideration of many biologic therapies) and refer to a specialist for further assessment. While waiting for specialist review, prescribe or continue maintenance ICS+LABA therapy. An 8- to 12-week trial of add-on treatment with montelukast may be considered in children from 2 years of age; this should be stopped if there is no clinical benefit after 12 weeks or if adverse effects occur.3
Referral to a paediatrician or paediatric respiratory physician should be considered when:
Recent updates to asthma guidelines for children under 12 years of age emphasise the importance of accurate diagnosis, including the use of spirometry and FeNO testing from 6 years of age. There is increasing recognition of the benefits of earlier initiation of maintenance ICS therapy in children to reduce the risk of exacerbations and long-term corticosteroid exposure. In contrast to current guidance for adolescents and adults, inhaled salbutamol remains the mainstay of as-needed symptom relief for children.
This article was finalised on 20 October 2026.
Conflicts of interest: Tim Jones is a member of the National Asthma Council’s Guidelines Committee. Tim is also the chair of the Royal Australian College of General Practitioners’ Child and Young Person’s Health Specific Interest Group, Board Director of Primary Health Tasmania and a member of the Federal Thriving Kids Advisory Group, for which he has received travel and accommodation support.
This article is peer reviewed.
Australian Prescriber welcomes Feedback.
General Practitioner, Lauderdale Medical Centre, Tasmania
Senior Medical Educator and Deputy Faculty Chair, The Royal Australian College of General Practitioners
Medical Educator, Emerging Minds